Calcineurin inhibitors are associated with a higher neoplastic risk, while mTOR inhibitors, particularly sirolimus, may reduce the risk of HCC recurrence and non-melanoma skin cancer. This evidence concerns the gene MTOR and non-melanoma skin carcinoma.